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Abstract
Background: The current international multicentre open-label, uncontrolled, real-world retrospective study aimed at evaluating
the effectiveness and safety of ombitasvir / paritaprevir / ritonavir + dasabuvir ± ribavirin (3D therapy) in treatment-naive and
treatment-experienced hepatitis C virus (HCV) genotype 1-infected (GT1) patients.
Methods: Adult patients with chronic HCV GT1 infection, scheduled for 3D therapy according to therapeutic guidelines, were eligi-
ble. Demographic and clinical data were collected retrospectively by reviewing individuals health records. The primary effectiveness
endpoint was the sustained virological response at 12 weeks following the end of treatment (SVR12).
Results: The participants in the current study consisted of 134 patients with HCV GT1 infection, including 10 liver transplant recip-
ients. SVR12 was achieved in 120 (96.8%) non-transplant and all liver transplant patients (100%). Significant improvement in liver
function tests were observed. Among 4 treatment failures, 2 patients were non-responders and 2 patients relapsed. OBV/PTV/r + DSV
± RBV regimen was well tolerated in most patients with treatment discontinuation due to adverse events in 3 patients. The most
frequent adverse events were asthenia (25.8%), fatigue (16.1%), skin pruritus (12.9%), and dyspepsia (11.3%).
Conclusions: The current real-life study demonstrated the effectiveness and safety of OBV/PTV/r + DSV ± RBV in patients with HCV
GT1, including patients with cirrhosis, a liver transplant recipient and the one who failed previous antiviral therapies.
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1. Background
Hepatitis C virus (HCV) is a blood-borne, positive sense,
single-stranded ribonucleic acid (RNA) virus of the fam-
ily Flaviviridae. HCV can cause mild to severe liver dis-
eases and is the most common cause of chronic hepatitis,
liver cirrhosis, and hepatocellular carcinoma (HCC). HCV
prevalence ranges 0.2% to 40% in different countries, af-
fecting over 170 - 200 million people worldwide. Chronic
infection with hepatitis C and related diseases are global
health problems and impose heavy financial burden on
the health systems and societies (1).
Based on genetic differences, the HCV species are clas-
sified into 6 genotypes (1 to 6) with several subtypes within
each genotype (2, 3). Genotype 1 (GT1) is the most common
genotype of HCV infection, accounting for 46% - 60% of
cases worldwide (4, 5). The subtypes genotype 1a (GT1a) and
genotype 1b (GT1b) are responsible for the vast majority of
GT1 infections (6).
In patients with HCV GT1 infection the rates of sus-
tained virologic response (SVR12) after treatment with pe-
gylated interferon and ribavirin (PegINF/RBV) were as low
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as 50% and 30% in non-transplant and liver transplant re-
cipients (6-8).
SVR12 rates increased approximately up to 60% - 80%
in HCV GT1-infected non-transplant patients (9, 10) and
up to 52% in liver transplant recipients since 2011, when
a new family of medicines known as first generation
direct-acting antivirals (DAAs) telaprevir and boceprevir
were developed and introduced for use in combination
with PegINF/RBV (8). PegINF, however, is associated with
substantial side effects, which affect adherence to the
interferon-based therapy (11).
The new interferon-free second-generation
DAA therapy (3D therapy) consisting of ombitasvir
(OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ±
ribavirin (RBV) improved the efficacy, safety, and tolerabil-
ity of the treatment of chronic HCV infection. In clinical
studies, the regimen consisting of OBV/PTV/r + DSV ± RBV
was highly efficacious to treat HCV GT1a or GT1b infection,
including patients with compensated cirrhosis, liver
transplant or human immunodeficiency virus 1 (HIV-1)
co-infection. The observed SVR12 rate ranged from 92% to
100% (8, 12-19).
The combination of the NS5A inhibitor ombitasvir, the
NS3/4A protease inhibitor paritaprevir boosted with riton-
avir, and the NS5B polymerase inhibitor dasabuvir with or
without ribavirin was approved to treat chronic HCV GT1
infection in the United Stated in December 2014 and in Eu-
ropean Union in January 2015 (17, 20).
The current multicentre open-label, uncontrolled,
real-world study aimed at evaluating the efficacy and safety
of the OBV/PTV/r + DSV ± RBV in the early access program
in Lithuania and Latvia and in clinical practice in Lithuania
from January 2015 to November 2016.
2. Methods
2.1. Study Population
Adult patients with chronic HCV (CHC) infection
treated with OBV/PTV/r + DSV ± RBV at Vilnius university
hospital Santaros Klinikos centre of hepatology, gas-
troenterology and dietetics, centre of infectious diseases
(Vilnius, Lithuania) and Riga East university hospital,
infectology centre of Latvia, hepatology department (Riga,
Latvia) from January 2015 to November 2016 were enrolled
into the current study. Patients were eligible for OBV/PTV/r
+ DSV ± RBV treatment if infected with HCV GT1a, 1b, or
1a/b, were treatment-naïve or previously treated with
PegINF/RBV ± first generation protease inhibitor telapre-
vir or boceprevir, and/or had advanced fibrosis (METAVIR
stage F3 - F4). Eligible patients also included the ones with
post-orthotopic liver transplantation and patients with F2
fibrosis stage with contraindications to interferon-based
therapy or not tolerate to PegINF/RBV regimen. Patients
with advanced liver decompensation and Child-Pugh C
cirrhosis were excluded from the study.
2.2. Study Design
It was an international multicentre open-label, un-
controlled, real-world retrospective study conducted in
Lithuania (2 centres) and Latvia (1 centre). The local hospi-
tals ethics committees in each country approved the study.
The treatment of the OBV/PTV/r + DSV±RBV for the part
of patients was obtained within an early access patient pro-
gram from January 2015 and written informed consent was
obtained from each participitant. The therapy for the re-
maining patients was 100% reimbursed in October 29, 2015
in Lithuania and January 1, 2016 in Latvia.
Clinical assessments, concomitant treatments and
other medical decisions were taken at the discretion of the
treating physicians according to standard clinical practice.
In accordance to the approved summaries of product char-
acteristics, patients received a combination of OBV/PTV/r
(25 mg, 150 mg, and 100 mg daily) and DSV (250 mg daily)
with or without weight-based RBV (1000 - 1200 mg daily)
for 12 or 24 weeks. Patients infected with GT1a were treated
with OBV/PTV/r + DSV + RBV for 12 weeks (the ones with-
out cirrhosis) or for 24 weeks (the ones with compen-
sated cirrhosis and all patients undergone liver transplan-
tation). All patients with GT1b-infection were treated with
OBV/PTV/r + DSV ± RBV for 12 weeks. The dose of RBV was
adjusted during the course of treatment according to labo-
ratory test results and tolerability. In liver transplant recip-
ients, the doses of immunosuppressive agents (tacrolimus
and cyclosporine) were reduced according to plasma con-
centrations.
Patients data were collected retrospectively by review-
ing individual’s health record. Baseline demographic and
clinical data included gender, age, body mass index (BMI),
fibrosis stage (METAVIR scoring system), HCV genotype,
previous antiviral treatment, and response to previous
treatments. Fibrosis was evaluated by liver biopsy and/or
transient elastography (FibroScan). The Child-Pugh score
system was used to define clinical status.
Laboratory parameters and adverse events (AE) were
assessed at the baseline (the day 0), the weeks 1, 2, 4, 8, at
the end of treatment (EOT, week 12 or 24), and at the follow-
up (FU, 12 weeks after EOT), or until the premature discon-
tinuation of treatment. Laboratory data included HCV ri-
bonucleic acid (RNA) level, alpha-fetoprotein (AFP), inter-
national normalised ratio (INR), albumins, bilirubin, ala-
nine aminotransferase (ALT), aspartate aminotransferase
(AST), gamma-glutamyltransferase (GGT), serum creati-
nine, platelets count (PLT), haemoglobin (Hb). HCV-RNA
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level was measured using real-time polymerase chain reac-
tion (real-time PCR) according to standard methods at the
baseline, at the EOT, and at FU visit.
At each visit, patients were interviewed to identify any
adverse event.
2.3. Virologic and Safety Assessment
The primary effectiveness endpoint was SVR12, follow-
ing the end of treatment. The secondary endpoints in-
cluded end-of-treatment response (undetectable HCV RNA
at the end of treatment), virologic relapse (undetectable
HCV RNA at the end of treatment, but positive within 12
weeks post treatment), and non-response (HCV RNA being
detectable at the end of treatment).
Safety endpoints included adverse events (AE) and lab-
oratory abnormalities.
2.4. Serological and Molecular Diagnosis of Viral Spread
In the first step, to evaluate the exposure rate the pres-
ence of total anti-HCV antibodies was determined using
4th generation anti-HCV enzyme-linked immunosorbent
assay (ELISA) kit on serum samples according to the manu-
facturer’s instructions.
Then, to investigate the current molecular state in
cases with positive HCV antibody, viral RNA genome was ex-
tracted from sera by a commercially available kit. In addi-
tion, for more accurate evaluation, a commercial real-time
PCR detection method was employed to confirm the pres-
ence of viral genome inside the serum. Finally, a simple
genotyping assay was performed on family members with
PCR positive results (21).
2.5. Statistical Analysis
The descriptive statistics and statistical tests for group
comparisons were applied for data analysis. Means of 2 de-
pendent samples were compared using the paired samples
t test. For categorical variables, differences between the 2
groups were evaluated using the Pearson chi-square test.
Statistical differences were interpreted at 5% (2-sided) sig-
nificance level. Statistical analyses were performed using
IBM SPSS 20.0 and Microsoft Excel 2010 software.
3. Results
3.1. Patients disposition
The current study participants consisted of 134 pa-
tients with HCV GT-1 infection, including 10 liver trans-
plant recipients. Patients demographics and baseline clin-
ical characteristics are presented in Table 1. Among non-
transplant patients, the most prevalent HCV subtype was
1b (88.7%). Majority of non-transplant patients (72.6%)
were previously treated with PegIFN/RBV, 26 (21.0%) pa-
tients received triple therapy with PegIFN/RBV, and telapre-
vir or boceprevir. All except one liver transplant recipient
were infected with HCV GT-1b, and 8 (20.0%) patients were
treatment-experienced.
A total of 120 non-transplant patients received a 12-
week treatment, while all 10 liver transplant recipients
and 4 GT-1a infected non-transplant patients with compen-
sated cirrhosis were treated for 24 weeks; 104 patients also
received RBV. The scheduled treatment was completed for
121 (97.4%) non-transplant patients and all 10 (100.0%) liver
transplanted recipients. Three non-transplant patients
prematurely discontinued the treatment due to AEs.
3.2. Effectiveness
HCV RNA was undetectable at the EOT in 122 (98.4%)
non-transplant patients. SVR12 was achieved in 120 (96.8%)
non-transplant patients. SVR12 rates were high across dif-
ferent subgroups (Table 2). All liver transplant recipi-
ents (100%) achieved virological suppression at EOT and 12
weeks after the treatment (SVR12).
Among 4 treatment failures, 2 patients were non-
responders and 2 patients relapsed. Three patients also
failed their previous antiviral treatment. Characteristics of
patients with treatment failures are summarized in Table 3.
In non-transplant patients, the mean ALT level signifi-
cantly decreased from 95.7 IU/L at baseline to 40.7 IU/L after
the first week of the treatment (P ≤ 0.001) and to 26.7 IU/L
at the EOT (P ≤ 0.001). AST, γ-GT, and AFP levels and liver
stiffness also significantly improved at the EOT as com-
pared to baseline (Table 4, Figures 1 - 2). At the EOT, ALT, AST,
and γ-GT levels were normalised in89.0%, 95.3%, and 67.6%
of patients with elevated baseline levels, respectively. Sim-
ilarly, significant improvement in liver function tests was
observed in liver transplant recipients (Table 4, Figures 3 -
4).
3.3. Safety
There were no deaths during the treatment and follow-
up period; 53 (42.7%) of non-transplant patients reported
at least 1 adverse event. Three patients discontinued the
treatment prematurely due to AEs (all of them received rib-
avirin). One patient discontinued the treatment because of
psoriasis exacerbation on the day 3, one patient - because of
exacerbation of depression at the week 5, and one patient -
due to elevation of liver transaminases at the week 9.
The most common AEs were asthenia (25.8%), fatigue
(16.1%), skin pruritus (12.9%), dyspepsia (11.3%), and insom-
nia (9.7%) (Table 5). AEs were mostly mild and did not re-
quire medical intervention. AEs occurred more frequently
in patients treated with ribavirin.
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Figure 1. Laboratory and Instrumental Data: Non-transplant Patients
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Figure 2. Laboratory and Instrumental Data: Non-transplant Patients
RBV, ribavirin; ULN, upper limit normal; ALT, alanine
transaminase
The incidence of laboratory abnormalities was uncom-
mon in non-transplant patients and occurred exception-
ally in those receiving ribavirin (Table 5, Figure 5). Because
of abnormal laboratory test results, ribavirin dose was re-
duced in 27 (28.4%) non-transplant patients and 3 (30.0%)
liver transplant recipients; ribavirin was discontinued in
10 (10.5%) non-transplant patients and 2 (20.0%) liver trans-
plant recipient.
In 6 non-transplant patients and 8 liver transplant re-
cipients, the haemoglobin level dropped below 100 g/L.
None of such patients received erythropoietin or blood
transfusion.
4. Discussion
Randomized controlled clinical trials are the gold stan-
dard to establish the efficacy and safety of any medicinal
product. However, clinical trials are conducted under stan-
dardized conditions in homogenous patient populations,
which is very different from real world situation. Due to
differences between patients included in the controlled
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Figure 3. Laboratory and Instrumental Data: Liver Transplant Recipients
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Figure 4. Laboratory and Instrumental Data: Liver Transplant Recipients









































Figure 5. RBV (+) versus RBV (-): On-treatment Laboratory Abnormalities
studies and the ones encountered in everyday life, extrap-
olation of clinical trial results to the entire patient popu-
lation is difficult. Real-world studies are conducted in a
heterogeneous mixture of patients, often older and with
different comorbidities and risk factors. Hence, real-life
data better reflect the target population and the real ef-
ficacy and safety of many drugs. For these reasons, real-
world studies gain more importance in understanding
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Table 1. Demographic and Baseline Clinical Characteristics
Characteristics Non-Transplant
Patient, N = 124
Liver Transplant
Recipient, N = 10
Gender, n (%)
Male 62 (50.0%) 4 (40.0%)
Female 62 (50.0%) 6 (60.0%)
Age, year
Mean± SD 54.6± 11 50.7± 8.0
Range (min -
max)
24 - 83 42 - 63
BMI, kg/m2
Mean± SD 28.1± 4.9 25.6± 4.2
Range (min -
max)
18 - 42 20 - 31
Genotype
1a 7 (5.6%) 0
1b 110 (88.7%) 9 (90.0%)
1a/b 7 (5.6%) 1 (10.0%)
Fibrosis stage
F1 0 2 (20.0%)
F2 10 (8.1%) 3 (30.0%)
F3 43 (34.7%) 1 (10.0%)
F4 71 (57.3%) 0
Unknown 0 4 (40.0%)
HCV-RNA, IU/mL
Mean± SD 5.0× 106± 9.5× 106 8.7× 106± 1.4× 107
Range (min -
max)
8.7× 103 - 8.8× 107 1.6× 103 - 5.1× 107
Antiviral treatment
history




26 (21.0%) 1 (10.0%)
Null-
responders
36 (29.0%) 4 (40.0%)
Partial
responders
18 (14.5%) 1 (10.0%)
Relapsers 27 (21.8%) 2 (20.0%)
Discontinued
due to AE
9 (7.8%) 1 (10.0%)
Abbreviations: AE, adverse event; BMI, body mass index; HCV, hepatitis C virus;
RNA, ribonucleic acid; SD, standard deviation.
treatment effectiveness and safety profiles in the general
patient population.
Since the marketing authorisation of OBV/PTV/r and
Table 2. Rates of Virological Response at EOT and SVR12
Patients Group VR at EOT SVR12
Non-transplant patients 122/124 (98.4) 120/124 (96.8)
Cirrhotic patients 70/72 (97.2) 69/72 (95.8)
Liver transplant recipients 10/10 (100.0) 10/10 (100.0)
Non-transplant patients according to
treatment history
Naive 34/35 (97.1) 34/35 (97.1)
Null-responders to PegIFN/RBV +
telaprevir or Boceprevir
7/8 (87.5) 7/8 (87.5)
Null-responders to PegIFN/RBV 31/31 (100.0) 30/31 (96.8)
Partial responders 18/18 (100.0) 18/18 (100.0)
Relapsers 27/27 (100.0) 26/27 (96.3)
Abbreviations: EOT, end of treatment; PegIFN, pegylated interferon; RBV, rib-
avirin; VR, virologic response; SVR12, sustained virologic response at 12 weeks
post-treatment.
DSV both by the US food and drug administration (FDA)
and the European medicines agency in 2015, a number of
real-world studies are conducted (22-27). A meta-analysis
of 20 unique patient cohorts across 25 studies encompass-
ing 5158 patients reported the overall SVR12 rates of 96.8%
(95% confidence interval (CI): 95.8-97.7) in GT1-infected pa-
tients and 98.9% (95% CI 94.2 - 100) in GT4-infected patients.
SVR12 rates were consistently high irrespective of cirrhosis
status or prior HCV treatment experience (28).
The current study analysed real-world effectiveness of
OBV/PTV/r + DSV ± RBV in 134 patients with HCV GT-1 infec-
tion treated in 3 health care centres in Lithuania and Latvia.
The SVR12 rate was 120 (96.8%) in non-transplant patients
and 10 (100.0%) in liver transplant recipients. The study
population included a considerable number of treatment-
experienced patients (73%) and cirrhotic patients (57%). All
the same, more than 90% of them achieved SVR12. Thus, the
current study results were consistent with high SVR12 rates
(97%-100%) noted earlier in real-world studies (25-27).
The 3 patients that failed to achieve SVR12 were
treatment-experienced and 1 was treatment-naïve. Of
them, 3 were infected with HCV GT1b and 1 with GT1a/b.
Three patients had liver cirrhosis. Patients with cirrhosis
and the ones that failed previous antiviral therapies were
considered as difficult-to-treat population (12, 18, 19).
The frequency of discontinuation due to adverse
events in the current study was low (2.2%) and similar to
those of the other real-world studies (~ 2.5%) (24, 28). Ad-
verse events reported in the current study were mostly
mild and more frequent in liver transplant recipients and
in patients receiving ribavirin.
As for all real-life studies, the current study had a few
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Table 3. Demographic and Clinical Characteristics of Patients with Virologic Failure
Patient No. 1 Patient No. 2 Patient No. 3 Patient No. 4
Gender Male Male Male Male
Age, years 43 53 38 45
Fibrosis stage F4 F4 F3 F4









treatment with OBV/PTV/r +
DSV± RBV
24 weeks 12 weeks 12 weeks 12 weeks
RBV 1200 mg (RBV dose was not
reduced)
1200 mg (RBV dose was not
reduced)
1200 mg (RBV dose was not
reduced)
1200 mg (RBV dose was not
reduced)
HCV-RNA, IU/mL
Day 0 3490000 2610000 142500 5790000
EOT 374000 Undetected Undetected -
FU - 3210000 1750000 -
Adverse events Fatigue Bleeding from the
nose
- Asthenia, Fatigue, Insomnia,
ALT↑5xULN, (273 µM/L at the
week 4)
Skin itching, Rash, (psoriasis
exacerbation)
Abbreviations: ALT, alanine transaminase; DSV, dasabuvir; HCV, hepatitis C virus; OBV, ombitasvir; PegINF, pegylated interferon; PTV, paritaprevir; r, ritonavir; RNA, ri-
bonucleic acid; RBV, ribavirin; ULN, upper limit of normal.
inherent limitations and its results should be interpreted
with caution. Namely, the study was uncontrolled, retro-
spective, and there was no external monitoring of the col-
lected data. Clinical examinations were restricted to the
ones performed in a routine manner. In addition, the study
included a relatively small number of patients and this pre-
cluded more thorough subgroup analyses.
4.1. Conclusions
In conclusion, the current real-life study demonstrated
the effectiveness and safety of OBV/PTV/r + DSV ± RBV to
treat the heterogeneous population of patients with HCV
GT1 infection including the ones with cirrhosis, liver trans-
plant recipients, and patients who failed previous antiviral
therapies.
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